van Zaanen HC - Search Results

1

A simple and sensitive method for determining plasma cell isotype and monoclonality in bone marrow using flowcytometry.

van Zaanen HC, Vet RJ, de Jong CM, von dem Borne AE, van Oers MH. van Zaanen HC, et al. Among authors: van oers mh. Br J Haematol. 1995 Sep;91(1):55-9. doi: 10.1111/j.1365-2141.1995.tb05244.x. Br J Haematol. 1995. PMID: 7577652

2

Interleukin-6, a new target for therapy in multiple myeloma?

van Oers MH, van Zaanen HC, Lokhorst HM. van Oers MH, et al. Among authors: van zaanen hc. Ann Hematol. 1993 May;66(5):219-23. doi: 10.1007/BF01738469. Ann Hematol. 1993. PMID: 8507716 Review.

3

Corynebacterium CDC group JK (Corynebacterium jeikeium) sepsis in haematological patients: a report of three cases and a systematic literature review.

van der Lelie H, Leverstein-Van Hall M, Mertens M, van Zaanen HC, van Oers RH, Thomas BL, von dem Borne AE, Kuijper EJ. van der Lelie H, et al. Among authors: van oers rh, van zaanen hc. Scand J Infect Dis. 1995;27(6):581-4. doi: 10.3109/00365549509047071. Scand J Infect Dis. 1995. PMID: 8685637 Review.

4

Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.

van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard JM, Warnaar SO, Lokhorst HM, van Oers MH. van Zaanen HC, et al. Among authors: van oers mh. J Clin Invest. 1996 Sep 15;98(6):1441-8. doi: 10.1172/JCI118932. J Clin Invest. 1996. PMID: 8823310 Free PMC article. Clinical Trial.

5

Modulation of chronic excessive interleukin-6 production in multiple myeloma does not affect thyroid hormone concentrations.

van Zaanen HC, Romijn JA, Sauerwein HP, Lokhorst HM, Warnaar SO, Aarden LA, Endert E, van Oers MH. van Zaanen HC, et al. Among authors: van oers mh. Metabolism. 1997 Nov;46(11):1343-8. doi: 10.1016/s0026-0495(97)90242-0. Metabolism. 1997. PMID: 9361697

6

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.

van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der Lelie J, van Oers MH. van Zaanen HC, et al. Among authors: van der lelie j, van oers mh. Br J Haematol. 1998 Aug;102(3):783-90. doi: 10.1046/j.1365-2141.1998.00835.x. Br J Haematol. 1998. PMID: 9722307 Free article.

7

Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.

Van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, Van Oers MH. Van Zaanen HC, et al. Among authors: van oers mh. Leuk Lymphoma. 1998 Nov;31(5-6):551-8. doi: 10.3109/10428199809057614. Leuk Lymphoma. 1998. PMID: 9922045 Clinical Trial.

8

Thiamine deficiency in hematologic malignant tumors.

van Zaanen HC, van der Lelie J. van Zaanen HC, et al. Among authors: van der lelie j. Cancer. 1992 Apr 1;69(7):1710-3. doi: 10.1002/1097-0142(19920401)69:7<1710::aid-cncr2820690711>3.0.co;2-d. Cancer. 1992. PMID: 1551055

9

Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity.

van Zaanen HC, van der Lelie H, Timmer JG, Fürst P, Sauerwein HP. van Zaanen HC, et al. Among authors: van der lelie h. Cancer. 1994 Nov 15;74(10):2879-84. doi: 10.1002/1097-0142(19941115)74:10<2879::aid-cncr2820741022>3.0.co;2-h. Cancer. 1994. PMID: 7954251 Clinical Trial.

10

Adult T-cell leukaemia and lymphoma: report of two cases and a brief review of the literature.

van Zaanen HC, Pegels JG. van Zaanen HC, et al. Neth J Med. 2002 Sep;60(8):330-3. Neth J Med. 2002. PMID: 12481881 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page